Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor smile

Journal of Biological Chemistry

Volumn 289, Issue 2, 2014, Pages 1079-1091

  Lee, Ji Min ^a,b   Gang, Gil Tae ^c   Kim, Don Kyu ^a,b   Kim, Yong Deuk ^a,b   Koo, Seung Hoi ^d   Lee, Chul Ho ^c   Choi, Hueng Sik ^a,b,e  

^a Nuclear Receptor Signals   (South Korea)

^b Chonnam National University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Korea University   (South Korea)

^e Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COREPRESSORS; HETERO DIMERS; LEUCINE ZIPPER PROTEINS; LIPOGENESIS; LIVER X RECEPTORS; NUCLEAR RECEPTORS; URSODEOXYCHOLIC ACID;

BIOCHEMISTRY; BIOLOGY;

GENE EXPRESSION;

ACETYL COENZYME A CARBOXYLASE; FATTY ACID SYNTHASE; LIVER X RECEPTOR ALPHA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; NUCLEAR RECEPTOR COREPRESSOR; SMALL HETERODIMER PARTNER INTERACTING LEUCINE ZIPPER PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACC GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FAS GENE; GENE; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SMILE GENE; SREBP 1C GENE;

AMP-ACTIVATED KINASE (AMPK); BILE ACID; COREPRESSOR; LIPOGENESIS; LIVER X RECEPTOR (LXR); NUCLEAR RECEPTORS; SMALL HETERODIMER PARTNER INTERACTING LEUCINE ZIPPER PROTEIN (SMILE); STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 (SREBP-1C); TRANSCRIPTION REPRESSOR;

ACETYL-COA CARBOXYLASE; ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELLS, CULTURED; DIET, HIGH-FAT; FATTY ACID SYNTHASE, TYPE I; HEK293 CELLS; HEP G2 CELLS; HUMANS; HYDROCARBONS, FLUORINATED; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; ORPHAN NUCLEAR RECEPTORS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SULFONAMIDES; TRANSCRIPTIONAL ACTIVATION; URSODEOXYCHOLIC ACID;

EID: 84891909092     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.491522     Document Type: Article

References (43)

1. Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., and Mangelsdorf, D. J. (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9, 1033-1045
2. Janowski, B. A., Grogan, M. J., Jones, S. A., Wisely, G. B., Kliewer, S. A., Corey, E. J., and Mangelsdorf, D. J. (1999) Structural requirements of ligands for the oxysterol liver X receptors LXR-and LXR-. Proc. Natl. Acad. Sci. U.S.A. 96, 266-271
3. Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., Lustig, K. D., and Shan, B. (2000) Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831-2838
4. Teboul, M., Enmark, E., Li, Q., Wikström, A. C., Pelto-Huikko, M., and Gustafsson, J. A. (1995) OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. U.S.A. 92, 2096-2100
5. Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., and Vidal, H. (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferatoractivated receptors and liver X receptor-in humans. No alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46, 1319-1327
6. Grefhorst, A., Elzinga, B. M., Voshol, P. J., Plösch, T., Kok, T., Bloks, V. W., van der Sluijs, F. H., Havekes, L. M., Romijn, J. A., Verkade, H. J., and Kuipers, F. (2002) Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277, 34182-34190
7. Gbaguidi, G. F., and Agellon, L. B. (2004) The inhibition of the human cholesterol 7-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor-and peroxisome proliferator-activated receptor-heterodimer. Nucleic Acids Res. 32, 1113-1121
8. Eberlé, D., Hegarty, B., Bossard, P., Ferré, P., and Foufelle, F. (2004) SREBP transcription factors. Master regulators of lipid homeostasis. Biochimie 86, 839-848
9. Repa, J. J., Liang, G., and Ou, J. (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP1) by oxysterol receptors, LXR-and LXR-. Genes Dev. 14, 2819-2830
10. Li, Y., Bolten, C., and Bhat, B. G. (2002) Induction of human liver X receptor-gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16, 506-514
11. Li, X., Zhang, S., Blander, G., Tse, J. G., Krieger, M., and Guarente, L. (2007) SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell. 28, 91-106
12. Nedumaran, B., Kim, G. S., Hong, S., Yoon, Y. S., Kim, Y. H., Lee, C. H., Lee, Y. C., Koo, S. H., and Choi, H. S. (2010) Orphan nuclear receptor DAX-1 acts as a novel corepressor of liver X receptor-and inhibits hepatic lipogenesis. J. Biol. Chem. 285, 9221-9232
13. Lu, R., and Misra, V. (2000) Zhangfei. A second cellular protein interacts with herpes simplex virus accessory factor HCF in a manner similar to Luman and VP16. Nucleic Acids Res. 28, 2446-2454
14. Hogan, M. R., Cockram, G. P., and Lu, R. (2006) Cooperative interaction of Zhangfei and ATF4 in transactivation of the cyclic AMP response element. FEBS Lett. 580, 58-62
15. Xie, Y. B., Lee, O. H., Nedumaran, B., Seong, H. A., Lee, K. M., Ha, H., Lee, I. K., Yun, Y., and Choi, H. S. (2008) SMILE, a new orphan nuclear receptor SHP-interacting protein, regulates SHP-repressed estrogen receptor transactivation. Biochem. J. 416, 463-473
16. Xie, Y. B., Nedumaran, B., and Choi, H. S. (2009) Molecular characterization of SMILE as a novel corepressor of nuclear receptors. Nucleic Acids Res. 37, 4100-4115
17. Xie, Y. B., Park, J. H., Kim, D. K., Hwang, J. H., Oh, S., Park, S. B., Shong, M., Lee, I. K., and Choi, H. S. (2009) Transcriptional corepressor SMILE recruits SIRT1 to inhibit nuclear receptor estrogen receptor-related receptor-transactivation. J. Biol. Chem. 284, 28762-28774
18. Misra, J., Chanda, D., Kim, D. K., Li, T., Koo, S. H., Back, S. H., Chiang, J. Y., and Choi, H. S. (2011) Curcumin differentially regulates endoplasmic reticulum stress through transcriptional corepressor SMILE (small heterodimer partner-interacting leucine zipper protein)-mediated inhibition of CREBH (cAMP responsive element-binding protein H). J. Biol. Chem. 286, 41972-41984
19. López-Mateo, I., Villaronga, M. Á., Llanos, S., and Belandia, B. (2012) The transcription factor CREBZF is a novel positive regulator of p53. Cell Cycle 11, 3887-3895
20. Lee, J. H., Lee, G. T., Kwon, S. J., Jeong, J., Ha, Y. S., Kim, W. J., and Kim, I. Y. (2012) CREBZF, a novel Smad8-binding protein. Mol. Cell. Biochem. 368, 147-153
21. Trauner, M., Claudel, T., Fickert, P., Moustafa, T., and Wagner, M. (2010) Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 28, 220-224
22. Omata, M., Yoshida, H., Toyota, J., Tomita, E., Nishiguchi, S., Hayashi, N., Iino, S., Makino, I., Okita, K., Toda, G., Tankkawa, K., Kumada, H., and Japanese C-Viral Hepatitis Network. (2007) A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56, 1747-1753
23. Copaci, I., Micu, L., Iliescu, L., and Voiculescu, M. (2005) New therapeutical indications of ursodeoxycholic acid. Rom. J. Gastroenterol. 14, 259-266
24. Beuers, U., Boyer, J. L., and Paumgartner, G. (1998) Ursodeoxycholic acid in cholestasis. Potential mechanisms of action and therapeutic applications. Hepatology 28, 1449-1453
25. Arisawa, S., Ishida, K., Kameyama, N., Ueyama, J., Hattori, A., Tatsumi, Y., Hayashi, H., Yano, M., Hayashi, K., Katano, Y., Goto, H., Takagi, K., and Wakusawa, S. (2009) Ursodeoxycholic acid induces glutathione synthesis through activation of PI3K/Akt pathway in HepG2 cells. Biochem. Pharmacol. 77, 858-866
26. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., and Hotamisligil, G. S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137-1140
27. Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., Bonnefont-Rousselot, D., Bastard, J. P., Rivière, M., Spénard, J., and FRESGUN (2011) A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J. Hepatol. 54, 1011-1019
28. Watanabe, M., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., and Auwerx, J. (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP1. J. Clin. Invest. 113, 1408-1418
29. Huuskonen, J., Fielding, P. E., and Fielding, C. J. (2004) Role of p160 coactivator complex in the activation of liver X receptor. Arterioscler. Thromb. Vasc. Biol. 24, 703-708
30. Heery, D. M., Hoare, S., Hussain, S., Parker, M. G., and Sheppard, H. (2001) Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 276, 6695-6702
31. Talukdar, S., Bhatnagar, S., Dridi, S., and Hillgartner, F. B. (2007) Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-gene transcription by the liver X receptor agonist T0-901317. J. Lipid Res. 48, 2647-2663
32. Lepage, G., Paradis, K., Lacaille, F., Sénéchal, L., Ronco, N., Champagne, J., Lenaerts, C., Roy, C. C., and Rasquin-Weber, A. (1997) Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J. Pediatr. 130, 52-58
33. Timsit, Y. E., and Negishi, M. (2007) CAR and PXR. The xenobioticsensing receptors. Steroids 72, 231-246
34. Watt, A. J., Garrison, W. D., and Duncan, S. A. (2003) HNF4. A central regulator of hepatocyte differentiation and function. Hepatology 37, 1249-1253
35. Heitzer, M. D., Wolf, I. M., Sanchez, E. R., Witchel, S. F., and DeFranco, D. B. (2007) Glucocorticoid receptor physiology. Rev. Endocr. Metab. Disord. 8, 321-330
36. Kay, H. Y., Kim, W. D., Hwang, S. J., Choi, H. S., Gilroy, R. K., Wan, Y. J., and Kim, S. G. (2011) Nrf2 inhibits LXR-dependent hepatic lipogenesis by competing with FXR for acetylase binding. Antioxid. Redox Signal. 15, 2135-2146
37. Brendel, C., Schoonjans, K., Botrugno, O. A., Treuter, E., and Auwerx, J. (2002) The small heterodimer partner interacts with the liverXreceptor-and represses its transcriptional activity. Mol. Endocrinol. 16, 2065-2076
38. Uzun, M. A., Koksal, N., Aktas, S., Gunerhan, Y., Kadioglu, H., Dursun, N., and Sehirli, A. O. (2009) The effect of ursodeoxycholic acid on liver regeneration after partial hepatectomy in rats with non-alcoholic fatty liver disease. Hepatol. Res. 39, 814-821
39. Poupon, R., and Poupon, R. E. (1995) Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol. Ther. 66, 1-15
40. Schoemaker, M. H., Conde de la Rosa, L., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L., and Moshage, H. (2004) Tauroursodeoxycholic acid protects rat hepatocytes from bile acidinduced apoptosis via activation of survival pathways. Hepatology 39, 1563-1573
41. Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., and Shan, B. (1999) Identification of a nuclear receptor for bile acids. Science 284, 1362-1365
42. Schoenfield, L. J., and Lachin, J. M. (1981) Chenodiol (chenodeoxycholic acid) for dissolution of gallstones, the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern. Med. 95, 257-282
43. Angulo, P. (2002) Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4, 37-44